Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,615 questions · 1,673 findings · 190 reviews · Headline outcomes only

No studies found 278 · 16.6%GRADE not reported 85 · 5.1%Very low 328 · 19.6%Low 460 · 27.5%Moderate 402 · 24%High 120 · 7.2%

Adjustable individualized fortification vs standard non‐individualized fortification

Culture‐proven late‐onset sepsis · promoting growth and development in very low birth weight infants receiving human milk

The review found no eligible studies for this question.

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Overall survival: Median length of · women with advanced EOC after primary IDS

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Progression‐free survival · women with advanced EOC after primary IDS

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Overall survival: Median length of · women with advanced ovarian cancer after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Progression‐free survival · women with advanced ovarian cancer after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Overall survival: Median length of · women with advanced EOC after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Progression‐free survival · women with advanced EOC after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Overall survival: Median length of · women with advanced EOC after primary IDS

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).

1 finding from 1 review

Targeted or adjustable individualized fortification vs standard non‐individualized fortification

Necrotising enterocolitis · promoting growth and development in very low birth weight infants receiving human milk

The review found no eligible studies for this question.

1 finding from 1 review

Targeted or adjustable individualized fortification vs standard non‐individualized fortification

Culture‐proven late‐onset sepsis · promoting growth and development in very low birth weight infants receiving human milk

The review found no eligible studies for this question.

1 finding from 1 review